MIRA Pharmaceuticals Announces Exclusive Licensing Agreement For Oral Ketamine Analog, Ketamir-2; Agreement Includes $3M Line Of Credit Extended By MIRALOGX To Fund Initial Development Of Ketamir-2
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals has entered into an exclusive licensing agreement for an oral ketamine analog, Ketamir-2. Additionally, MIRALOGX has extended a $3M line of credit to MIRA Pharmaceuticals to fund the initial development of Ketamir-2.
November 20, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals has obtained exclusive licensing for Ketamir-2 and received a $3M line of credit from MIRALOGX for its development.
The exclusive licensing agreement for Ketamir-2 positions MIRA Pharmaceuticals favorably in the market for this compound. The $3M line of credit from MIRALOGX provides necessary funding for the initial development phase, which could lead to positive investor sentiment and potential stock price increase in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100